Single-Agent Therapy After Left Atrial Appendage Closure: What the SIMPLAAFY Trial Found

A simpler regimen reduced the bleeding burden

For patients with atrial fibrillation undergoing left atrial appendage closure, the period immediately after implantation presents a therapeutic tension. Antithrombotic treatment is used to limit thrombus formation while the device surface heals, but patients selected for closure commonly have a substantial risk of bleeding—the same problem that may have made long-term anticoagulation difficult.

The randomized SIMPLAAFY trial directly examined whether that early treatment could be simplified. It compared two single-agent approaches—reduced-dose non–vitamin K antagonist oral anticoagulant therapy and aspirin alone—with dual antiplatelet therapy for 6 months after left atrial appendage closure.

Stroke rates were similar across the treatment strategies during follow-up, while bleeding occurred less often with single-agent therapy than with dual antiplatelet therapy. The practical signal is therefore about net treatment burden: adding a second antiplatelet agent did not produce an evident short-term stroke advantage, but it exposed patients to more bleeding.

That distinction matters. Similar observed event rates do not automatically prove that the strategies are equivalent, particularly when ischemic stroke is uncommon and a trial has limited power for rare outcomes. The findings nevertheless challenge the assumption that greater antithrombotic intensity is necessarily safer after appendage closure.

The two simplified strategies should not be treated as interchangeable without considering their mechanisms. Reduced-dose oral anticoagulation suppresses coagulation-factor activity, whereas aspirin inhibits platelet activation. Finding acceptable outcomes with both approaches would support the broader concept of single-agent treatment, but it would not establish that aspirin and reduced-dose anticoagulation have identical efficacy for every patient or device.

How the randomized comparison was structured

SIMPLAAFY was a randomized clinical trial involving patients treated with left atrial appendage closure for atrial fibrillation. Participants were assigned to reduced-dose non–vitamin K antagonist oral anticoagulant monotherapy, aspirin monotherapy or dual antiplatelet therapy, with outcomes assessed over 6 months.

Randomization strengthens the causal interpretation of differences between the assigned strategies because it reduces confounding from baseline characteristics that often influence postprocedure prescribing. In routine care, for example, clinicians may preferentially give aspirin to patients perceived to have the greatest bleeding risk and anticoagulation to those perceived to have the greatest thrombotic risk. A nonrandomized comparison can therefore make a regimen appear safer or less effective because of who received it rather than because of the treatment itself.

The relevant clinical balance includes both thrombotic and hemorrhagic events. Ischemic stroke is the most consequential efficacy outcome, but device-related thrombus, systemic embolism and transient ischemic attack may also inform assessment of protection after closure. On the safety side, the severity and clinical consequences of bleeding matter more than event counts alone; major bleeding, intracranial bleeding and bleeding requiring hospitalization carry different implications than minor bleeding.

The supplied trial record supports the direction of the findings—similar stroke rates and less bleeding with single-agent treatment—but does not provide enough extractable detail in this brief to reproduce the randomized sample size, arm-specific event counts, effect estimates, confidence intervals or P values responsibly. Those figures should be confirmed against the final peer-reviewed tables before the results are used for protocol development or formal evidence grading.

What the evidence could change

Current US atrial fibrillation guidance recognizes percutaneous left atrial appendage occlusion as an option for selected patients who have a contraindication to long-term oral anticoagulation or a high risk of major bleeding. Postimplantation therapy remains a separate decision. It must account for the device used, procedural findings, bleeding history, renal function, other indications for anticoagulation or antiplatelet therapy, and the regimen supported by device labeling and clinical evidence.

SIMPLAAFY supports reconsidering routine dual antiplatelet therapy when a single agent can provide similar short-term protection with less bleeding. The clearest potential benefit is for patients in whom hemorrhagic risk is a central reason for choosing appendage closure. Reducing the number of antithrombotic drugs may also simplify medication reconciliation and reduce confusion during transitions between the implanting center, primary care and other specialists.

The trial does not support stopping antithrombotic therapy indiscriminately. Nor does it establish one universal regimen for all patients after closure. A person with another indication for anticoagulation, a recent coronary stent, device-related thrombus or a significant procedural complication may require a different strategy from the randomized pathways studied.

Implementation also requires attention to terminology. “Reduced dose” should refer to the regimen actually evaluated in the trial or to a dose supported by the applicable drug labeling and patient characteristics. It should not be interpreted as permission to select an untested dose. Likewise, aspirin monotherapy should be understood as an active antithrombotic strategy rather than an absence of treatment.

For policymakers and health systems, the study raises a protocol question rather than settling it outright. Standardized pathways could potentially reduce bleeding and medication complexity, but any change should preserve exceptions for competing indications and include surveillance for neurologic events, clinically important bleeding and device-related thrombus.

Important uncertainties remain

The follow-up period was 6 months, so the trial primarily informs early postimplantation management. It cannot determine whether small differences in ischemic risk emerge later, although postclosure regimens often focus on the period of device healing.

Rare outcomes create a second limitation. Comparable stroke rates may reflect genuinely comparable protection, but they can also result from too few events to reveal a clinically important difference. Interpretation therefore depends on the confidence intervals and the trial’s prespecified statistical framework, not solely on whether a conventional significance threshold was crossed.

Generalizability also requires scrutiny. Results may vary with the closure device, implantation technique, imaging surveillance, baseline bleeding risk and regional practice patterns. The trial’s funding and investigator conflicts should be reviewed in the published disclosure statements, particularly if a device or pharmaceutical manufacturer supported the work.

Finally, SIMPLAAFY evaluates treatment strategies, not every possible drug and dose within those strategies. Extrapolation to agents, dose reductions or durations not studied in the randomized trial would go beyond the evidence.

Questions clinicians ask

Does SIMPLAAFY show that dual antiplatelet therapy is unnecessary after every closure procedure?

No. It supports single-agent treatment as a potentially safer 6-month strategy in patients resembling the trial population, but it does not eliminate individualized decisions. Device labeling, procedural findings, device-related thrombus and separate indications for anticoagulation or dual antiplatelet therapy can justify a different approach.

Is aspirin alone as effective as reduced-dose oral anticoagulation?

The trial reported similar stroke rates among the randomized strategies, but uncommon events can limit direct comparisons between the two single-agent groups. Without adequately powered head-to-head estimates and confidence intervals, the findings should not be interpreted as proof that aspirin and reduced-dose anticoagulation are equivalent in every clinical setting.

What is the main bedside implication?

The evidence supports weighing bleeding risk explicitly rather than defaulting to greater antithrombotic intensity after appendage closure. Over 6 months, single-agent therapy reduced bleeding while preserving similar observed stroke rates, making medication burden and hemorrhagic risk central considerations in postprocedure planning.

Can clinicians apply the findings beyond 6 months?

Not confidently. SIMPLAAFY directly addresses the first 6 months after closure, when healing and device-related thrombosis are principal concerns. Longer-term therapy should reflect the patient’s other cardiovascular indications, subsequent imaging and clinical events rather than an unsupported extrapolation of the randomized comparison.

References

1. Simplified Antithrombotic Therapy After Left Atrial Appendage Closure: The SIMPLAAFY Randomized Clinical Trial — JAMA, 2026 2. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation — Circulation, 2024 3. SCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure — Journal of the Society for Cardiovascular Angiography & Interventions, 2023